ArticleOncoimmunology2012
Melanoma-infiltrating dendritic cells: Limitations and opportunities of mouse models.
Article in Oncoimmunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 28 citations in OpenAlex.
- The impact of MITF expression on tumor-infiltrating lymphocytes in melanoma: Insights into immune microenvironment dynamics.Biomolecules & biomedicine · 2025Article
- Article
- Tailoring therapeutics via a systematic beneficial elements comparison between photosynthetic bacteria-derived OMVs and extruded nanovesicles.Bioactive materials · 2024Article
- A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance.Nature immunology · 2022Review
- Systemic immune responses to irradiated tumours via the transport of antigens to the tumour periphery by injected flagellate bacteria.Nature biomedical engineering · 2022Article
- Metabolism heterogeneity in melanoma fuels deactivation of immunotherapy: Predict before protect.Frontiers in oncology · 2022Review
- Viewing keloids within the immune microenvironment.American journal of translational research · 2022Review
- ESDN inhibits melanoma progression by blocking E-selectin expression in endothelial cells via STAT3.Cancer letters · 2021Article
- CD11c+CD163+ Cells and Signal Transducer and Activator of Transcription 3 (STAT3) Expression Are Common in Melanoma Leptomeningeal Disease.Frontiers in immunology · 2021Article
- Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy.Cancers · 2020Review
- Impact of anatomic site on antigen-presenting cells in cancer.Journal for immunotherapy of cancer · 2020Review
- Cell Communication Network Factor 4 (CCN4/WISP1) Shifts Melanoma Cells from a Fragile Proliferative State to a Resilient Metastatic State.Cellular and molecular bioengineering · 2020Article
- Characterization of the Signaling Modalities of Prostaglandin E2 Receptors EP2 and EP4 Reveals Crosstalk and a Role for Microtubules.Frontiers in immunology · 2020Article
- The Melding of Drug Screening Platforms for Melanoma.Frontiers in oncology · 2019Review
- Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy.Oncotarget · 2017Review
- Loss of MAPK-activated protein kinase 2 enables potent dendritic cell-driven anti-tumour T cell response.Scientific reports · 2017Article
- Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma.Frontiers in immunology · 2017Review
- Tumor-infiltrating dendritic cells in cancer pathogenesis.Journal of immunology (Baltimore, Md. : 1950) · 2015Review
- A novel therapy for melanoma developed in mice: transformation of melanoma into dendritic cells with Listeria monocytogenes.PloS one · 2015Article
- Current State of Animal (Mouse) Modeling in Melanoma Research.Cancer growth and metastasis · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
The infiltration of melanoma lesions by dendritic cells (DCs) has been suggested to play a tumorigenic role due to the capacity of DCs to induce tumor tolerance and promote angiogenesis as well as metastasis. However, it has also been shown that tumor-infiltrating DCs (TIDCs) induce antitumor responses and hence may be targeted in cost-effective therapeutic approaches to obtain patient-specific DCs that present relevant tumor antigens, without the need for ex vivo DC expansion or tumor antigen identification. Unfortunately, little is known about the composition, nature and function of TIDCs found in human melanoma. The development of mouse melanoma models has greatly contributed to the molecular understanding of melanoma immunology in mice, but many questions on TIDCs remain unanswered. Here, we discuss current knowledge about melanoma TIDCs in various mouse models with regard to their translational potential and clinical relevance.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.